Alagebrium chloride (ALT711)
(Synonyms: 阿拉氯胺; ALT711) 目录号 : GC33761
Alagebrium chloride (ALT711)是一种噻唑鎓衍生物，可断裂晚期糖基化终产物(AGE)交联。
Cas No.:341028-37-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Alagebrium chloride (ALT711) is a thiazolium derivative which breaks advanced glycation end products (AGE) crosslinks. Alagebrium chloride has been used to study the treatment of diastolic heart failure, arterial stiffness, diabetic nephropathy, and hypertension[1][2].
In vitro, human breast cancer MDA-MB-231 cells were embedded in collagen gels glycated with glucose or ribose at different concentrations. Samples were treated with 1mM Alagebrium chloride overnight for about 16h in media. Increases in cell spreading, contractility, migration velocity, distance travelled, and motile fraction due to glycation could be inhibited by Alagebrium chloride to disrupt AGEs[3]. Rat cardiomyocytes were treated with AGE-bovine serum albumin or Alagebrium chloride (10mg/L) for 48 hours in complete growth medium. Alagebrium chloride exerts protective effect on AGEs-treated cardiomyocytes by inhibiting the increased oxidative stress[4].
In vivo, the streptozotocin-induced diabetic rats were treated with 10mg/kg Alagebrium chloride for 4 weeks. Alagebrium chloride was mixed with pulverized standard chow to a final Alagebrium chloride concentration of 0.015% (wt/wt). Alagebrium chloride treatment in diabetic rats significantly inhibits neointimal hyperplasia and inhibited the increase in formation of connective tissue and extracellular matrix[5]. Wide-typed and RAGE-/- C57BL/6J diabetic mice were randomized to receive Alagebrium chloride by oral gavage at 1mg/kg/day for 24 weeks. Alagebrium chloride significantly attenuated diabetes-driven albuminuria, glomerulosclerosis, and tubulointerstitial expansion, restored renal mitochondrial ATP production, and reduced both cytosolic and mitochondrial superoxide generation[6]. Female non-obese diabetic (NOD) mice were either given no treatment or daily, subcutaneous injections of Alagebrium chloride (1mg/kg/day) for 50 days from day 50 to 100 of life. Alagebrium chloride therapy from modestly delayed the age of diabetes onset, but there were no differences in disease incidence. Female NODShiLt mice were received subcutaneous injections of Alagebrium chloride (1mg/kg/day) for 28–32 days from day 50 of life. Short-Term Therapy with Alagebrium chloride slightly Increases Insulin Secretion[7].
References:
[1] William C Little W C, Zile M R, Kitzman D W, et al. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail. 2005 Apr;11(3):191-5.
[2] Wang H F, Weihrauch D, Kersten J R, et al. Alagebrium inhibits neointimal hyperplasia and restores distributions of wall shear stress by reducing downstream vascular resistance in obese and diabetic rats. Am J Physiol Heart Circ Physiol. 2015 Oct;309(7):H1130-40.
[3] Rowe M M, Wang W J, Taufalele P V, Reinhart-King C A. AGE-breaker ALT711 reverses glycation-mediated cancer cell migration.Soft Matter. 2022 Nov 16;18(44):8504-8513.
[4] Guo Y, Lu M, Qian J, Cheng Y L. Alagebrium chloride protects the heart against oxidative stress in aging rats. J Gerontol A Biol Sci Med Sci. 2009 Jun;64(6):629-35.
[5] Kim J B, Song B W, Park S H, et al. Alagebrium chloride, a novel advanced glycation end-product cross linkage breaker, inhibits neointimal proliferation in a diabetic rat carotid balloon injury model. Korean Circ J. 2010 Oct;40(10):520-6.
[6] Tan A L Y, Sourris K C, Harcourt B E, et al. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2010 Mar;298(3):F763-70.
[7] Borg D J, Faridi P, Giam K L, et al. Short Duration Alagebrium Chloride Therapy Prediabetes Does Not Inhibit Progression to Autoimmune Diabetes in an Experimental Model. Metabolites. 2021 Jun 28;11(7):426.
Alagebrium chloride (ALT711)是一种噻唑鎓衍生物，可断裂晚期糖基化终产物(AGE)交联。Alagebrium chloride已被用于研究舒张性心力衰竭、动脉僵硬、糖尿病肾病和高血压的治疗[1][2]。
体外实验中，将人乳腺癌MDA-MB-231细胞包埋于经不同浓度葡萄糖或核糖糖化的胶原凝胶中。样本在培养基中用1mM Alagebrium chloride处理过夜约16h。糖化引起的细胞铺展、收缩性、迁移速度、迁移距离及运动分数的增加均可被Alagebrium chloride通过破坏AGEs而抑制[3]。大鼠心肌细胞在完全培养基中用AGE-牛血清白蛋白或Alagebrium chloride(10mg/L)处理48h。Alagebrium chloride通过抑制氧化应激的增加，对AGEs处理的心肌细胞发挥保护作用[4]。
体内实验中，链脲佐菌素诱导的糖尿病大鼠以10mg/kg Alagebrium chloride治疗4周。将Alagebrium chloride与粉碎的标准饲料混合至终浓度0.015% (wt/wt)。Alagebrium chloride治疗显著抑制糖尿病大鼠的新生内膜增生，并抑制结缔组织及细胞外基质的增加[5]。野生型和RAGE-/- C57BL/6J糖尿病小鼠被随机分组，通过口服灌胃给予1mg/kg/day Alagebrium chloride，持续24周。Alagebrium chloride显著减轻糖尿病驱动的白蛋白尿、肾小球硬化和肾小管间质扩张，恢复肾脏线粒体ATP生成，并减少胞质和线粒体超氧阴离子的产生[6]。雌性非肥胖糖尿病(NOD)小鼠不接受治疗或从第50天至第100天每日皮下注射Alagebrium chloride (1mg/kg/day)，共50天。Alagebrium chloride治疗略微延迟糖尿病发病年龄，但发病率无差异。雌性NODShiLt小鼠从第28至第32天接受皮下注射Alagebrium chloride(1mg/kg/day)，短期Alagebrium chloride治疗轻度增加胰岛素分泌[7]。
| Cell experiment [1]: | |
Cell lines | Human breast cancer MDA-MB-231 cells |
Preparation Method | MDA-MB-231 cells were embedded in collagen gels glycated with glucose or ribose. For Alagebrium chloride treated conditions, samples were treated with 1mM Alagebrium chloride overnight in media for 16h. |
Reaction Conditions | 1mM; 16h |
Applications | Increases in cell spreading, contractility, migration velocity, distance travelled, and motile fraction due to glycation could be inhibited by Alagebrium chloride to disrupt AGEs. |
| Animal experiment [2]: | |
Animal models | Male Sprague-Dawley rats |
Preparation Method | Healthy male Sprague-Dawley rats that weighed 200-250g received intraperitoneal injections of streptozotocin (STZ) at a dose of 80mg/kg. The rats, which develop diabetes, then received long-acting insulin (2U/day daily) after the STZ injection. Sixteen weeks later, rats were randomized into two study groups: an Alagebrium chloride (10mg/kg) treatment group and a control group. |
Dosage form | 10mg/kg; mixed into chow; daily for 4 weeks |
Applications | Alagebrium chloride treatment in diabetic rats significantly inhibits neointimal hyperplasia and inhibited the increase in formation of connective tissue and extracellular matrix. |
References: | |
| Cas No. | 341028-37-3 | SDF | |
| 别名 | 阿拉氯胺; ALT711 | ||
| Canonical SMILES | O=C(C1=CC=CC=C1)C[N+]2=CSC(C)=C2C.[Cl-] | ||
| 分子式 | C13H14ClNOS | 分子量 | 267.77 |
| 溶解度 | Water : 50 mg/mL (186.73 mM);DMSO : ≥ 25 mg/mL (93.36 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7345 mL | 18.6727 mL | 37.3455 mL |
| 5 mM | 746.9 μL | 3.7345 mL | 7.4691 mL |
| 10 mM | 373.5 μL | 1.8673 mL | 3.7345 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet